🔓
Sign in as a Member to unlock the full view of HR.5708. · Full carveout list, all affected companies, party defectors, and 30-day trade predictions.
Become a Member$29.99/mo already a Member? Sign in →
HR.5708 · 118TH CONGRESS

MCM PRV Reauthorization Act

Status
Dead
Official Source
Investability
48/100
Stage
COMMITTEE
Related Bills
0
Full Text
941 chars
Alive
No

What This Bill Does · Plain English

Summary
Plain-English summary not yet available for this bill. Check back after our next analysis run.

Frequently Asked Questions

Did HR.5708 pass?
HR.5708 did not pass and is no longer active. Final stage: COMMITTEE.

Full Bill Text

118 HR 5708 IH: MCM PRV Reauthorization Act U.S. House of Representatives 2023-09-26 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. I 118th CONGRESS 1st Session H. R. 5708 IN THE HOUSE OF REPRESENTATIVES September 26, 2023 Mr. Finstad (for himself and Mr. Phillips ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend the Federal Food, Drug, and Cosmetic Act to extend a priority review program to encourage treatments for agents that present national security threats. 1. Short title This Act may be cited as the MCM PRV Reauthorization Act . 2. Extension of priority review to encourage treatments for agents that present national security threats Section 565A(g) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–4a(g)) is amended by striking 2023 and inserting 2033 .
🔒 GovGreed Pro · Trading Intelligence on HR.5708 Get Access — $29.99/mo
Loading intelligence layer…
Bill text sourced from GovInfo.gov · public domain · last updated 2026-11-17. Plain-English summary, score breakdown, and trading-intelligence panels are GovGreed-original analysis derived from STOCK Act filings, SEC Form 4 disclosures, FEC contributions, and Senate LDA lobbying reports — all publicly filed federal records. GovGreed is not affiliated with the U.S. Government. Not financial advice. [live render]